Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 16;11(6):1008.
doi: 10.3390/cells11061008.

MicroRNA as a Potential Therapeutic Molecule in Cancer

Joanna Szczepanek  1 , Monika Skorupa  1   2 , Andrzej Tretyn  2
Affiliations
Review

MicroRNA as a Potential Therapeutic Molecule in Cancer

Joanna Szczepanek et al. Cells. .

Abstract

Small noncoding RNAs, as post-translational regulators of many target genes, are not only markers of neoplastic disease initiation and progression, but also markers of response to anticancer therapy. Hundreds of miRNAs have been identified as biomarkers of drug resistance, and many have demonstrated the potential to sensitize cancer cells to therapy. Their properties of modulating the response of cells to therapy have made them a promising target for overcoming drug resistance. Several methods have been developed for the delivery of miRNAs to cancer cells, including introducing synthetic miRNA mimics, DNA plasmids containing miRNAs, and small molecules that epigenetically alter endogenous miRNA expression. The results of studies in animal models and preclinical studies for solid cancers and hematological malignancies have confirmed the effectiveness of treatment protocols using microRNA. Nevertheless, the use of miRNAs in anticancer therapy is not without limitations, including the development of a stable nanoconstruct, delivery method choices, and biodistribution. The aim of this review was to summarize the role of miRNAs in cancer treatment and to present new therapeutic concepts for these molecules. Supporting anticancer therapy with microRNA molecules has been verified in numerous clinical trials, which shows great potential in the treatment of cancer.

Keywords: drug resistance; metastamiRs; miRNA; miRNA delivery systems; miRNA inhibition therapy; oncomiRs; replacement therapy; tumor suppressor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Approaches for miRNA-based therapies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bartel D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. doi: 10.1016/S0092-8674(04)00045-5. - DOI - PubMed
    1. Szczepanek J. Role of microRNA dysregulation in childhood acute leukemias: Diagnostics, monitoring and therapeutics: A comprehensive review. World J. Clin. Oncol. 2020;11:348–369. doi: 10.5306/wjco.v11.i6.348. - DOI - PMC - PubMed
    1. Esquela-Kerscher A., Slack F.J. Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer. 2006;6:259–269. doi: 10.1038/nrc1840. - DOI - PubMed
    1. Tessitore A., Cicciarelli G., Mastroiaco V., Del Vecchio F., Capece D., Verzella D., Fischietti M., Vecchiotti D., Zazzeroni F., Alesse E. Therapeutic Use of MicroRNAs in Cancer. Anti-Cancer Agents Med. Chem. 2015;16:7–19. doi: 10.2174/1871520615666150824153358. - DOI - PubMed
    1. Zhang B., Pan X., Cobb G.P., Anderson T.A. MicroRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007;302:1–12. doi: 10.1016/j.ydbio.2006.08.028. - DOI - PubMed